Alto Neuro beats, raises $120M private placement to fund ALTO-207 Phase 3

 

Alto Neuroscience beats Q4 2025 estimates with EPS -$0.46 and raises $120M private placement to fund ALTO-207 Phase 3

• Fiscal Q4 2025 non-GAAP EPS was -$0.46, improving 12% year-over-year and beating analyst estimates.
• Quarterly revenue was $0, yet exceeded revenue estimates, alongside continued investment in Alto's neuroscience pipeline.
• Private placement totals $120M at $20 per share to fund ALTO-207 Phase 3 trial in treatment-resistant depression.
• Pro forma cash of about $275M expected to fund ALTO-207 through planned Phase 3 TRD trial and potential NDA submission.
• Reported 2025 results, ending the year with $177M cash expected to fund operations into 2028.
• Advances ALTO-207, ALTO-101, ALTO-300 and ALTO-100 through key Phase 2b and proof-of-concept milestones.

https://finviz.com/quote.ashx?t=ANRO&p=d